Skip to main content
MSF.org
  • English
  • العربية
  • Español
  • Français
MSF medical guidelines
MSF medical guidelines

Main navigation

  • Home
  • Guidelines
  • Updates
  • Order
  • About
  • Favorites
  • Contact

All guidelines

Tuberculosis

Essential drugs

English العربية Spanish French

Clinical guidelines - Diagnosis and treatment manual

English العربية Spanish French

Essential obstetric and newborn care

English العربية French

Management of A CHOLERA EPIDEMIC

English French

Management of A MEASLES EPIDEMIC

English French

Tuberculosis

English French

Public health engineering

English French
  • Authors/Contributors
  • Introduction
  • Abbreviations and acronyms
  • Chapter 1: Introduction and epidemiology
  • Chapter 2: Clinical presentation
  • Chapter 3: Diagnosis and follow-up investigations
  • Chapter 4: Diagnostic algorithms for pulmonary tuberculosis (PTB) in adults and adolescents
  • Chapter 5: Diagnosis of tuberculosis in children
  • Chapter 6: Intensive case finding in HIV-infected individuals
  • Chapter 7: Case definitions for registration
  • Chapter 8: Tuberculosis drugs and treatment regimens
  • Chapter 9: Treatment of drug-susceptible tuberculosis
  • Chapter 10: Treatment of multidrug-resistant TB (MDR-TB)
  • Chapter 11: Treatment of mono- and poly-drug resistant tuberculosis (PDR-TB)
  • Chapter 12: Co-management and treatment of HIV in TB disease
  • Chapter 13: Adherence to tuberculosis treatment
  • Chapter 14: Tuberculosis infection control
  • Chapter 15: Follow-up of staff exposed to tuberculosis
  • Chapter 16: Treatment of latent tuberculosis infection
  • Chapter 17: Monitoring and evaluation
  • Appendices
    • Appendix 1. Xpert assays
    • Appendix 2. Interpretation of Xpert assay results
    • Appendix 3. Sputum specimen: collection, storage and shipment
    • Appendix 4. Sputum smear microscopy
    • Appendix 5. Time required for diagnostic test results
    • Appendix 6. Ventilated work station (VWS) and bio-safety cabinet (BSC)
    • Appendix 7. Lymph node fine needle aspiration
    • Appendix 8. Protein estimation
    • Appendix 9. Tuberculin skin test
    • Appendix 10. Drug information sheets and patient instructions for the treatment of tuberculosis
    • Appendix 11. Use of tuberculosis drugs in pregnant or breastfeeding women
    • Appendix 12. Dose adjustments in renal insufficiency
    • Appendix 13. Daily dose of tuberculosis drugs using fixed-dose combinations
    • Appendix 14. Monitoring of patients on drug-susceptible tuberculosis treatment
    • Appendix 15. Monitoring of patients on drug-resistant tuberculosis treatment
    • Appendix 16. Additional investigations in drug-resistant tuberculosis
    • Appendix 16. Basic TB infection control risk assessment tool
    • Appendix 17. Management of adverse effects
      • Gastrointestinal disorders
      • Neurotoxicity
      • Endocrine disorders
      • Dermatological disorders
      • Musculoskeletal disorders
      • Miscellaneous
    • Appendix 17. Air change per hour (ACH) measurement recommendations
    • Appendix 18. Compassionate use
    • Appendix 18. Advantages and disadvantages of ventilation techniques
    • Appendix 19. Drug interactions and overlapping toxicities
    • Appendix 19. Upper room ultraviolet germicidal irradiation (UVGI) system
    • Appendix 20. Treatment supporters
    • Appendix 21. Informing the patient
    • Appendix 23. Treatment card for patients on first-line anti-TB therapy
    • Appendix 24. Tuberculosis register for patients on first-line anti-TB therapy
    • Appendix 25. Treatment card for patients on second-line anti-TB therapy
    • Appendix 26. Tuberculosis register for patients on second-line anti-TB therapy
    • Appendix 27. Respirators
    • Appendix 27. Request form for microscopy and Xpert MTB/RIF
    • Appendix 28. Surgical masks
    • Appendix 28. Request form for sputum culture, LPA and DST
    • Appendix 29. BCG vaccine
    • Appendix 29. Sputum smear microscopy register
    • Appendix 30. Xpert MTB/RIF register
    • Appendix 31. Drug-o-gram
    • Appendix 32. Quaterly report
    • Appendix 33. Report on detection and enrolment of TB cases with rifampicin and multidrug-resistance
    • Appendix 34. Report of final outcomes of drug-resistant tuberculosis
    • Appendix 35. Check-list for the evaluation of a TB service

Breadcrumb

  • Home
  • Tuberculosis
  • Appendices

Appendix 17. Management of adverse effects

Select language:
Enter
Download
Comment
Return to top
On this page

     

     

    Update: January 2022

     

    • Gastrointestinal disorders
      • Abdominal pain
      • Diarrhoea
      • Epigastric pain
      • Hepatotoxicity
      • Metallic taste
      • Nausea and vomiting
    • Neurotoxicity
      • Depression
      • Headache
      • Optic neuritis
      • Ototoxicity
      • Peripheral neuropathy
      • Psychosis
      • Seizures
    • Endocrine disorders
      • Gynecomastia
      • Hypothyroidism
    • Dermatological disorders
      • Alopecia
      • Fungal infection
      • Photosensitivity
      • Skin reactions
    • Musculoskeletal disorders
      • Arthralgias
      • Tendinitis/tendon rupture
    • Miscellaneous
      • Electrolyte disorders
      • Haematologic disorders
      • Lactic acidosis
      • Nephrotoxicity
      • QT prolongation

     

     

    Path

    Book traversal links for Appendix 17. Management of adverse effects

    • Appendix 16. Basic TB infection control risk assessment tool
    • Gastrointestinal disorders

    Send feedback about this page or ask a general question

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
    MSF medical guidelines
    MSF medical guidelines
    © Médecins Sans Frontières 2023

    Footer

    • Disclaimer
    • Cookie Policy
    • Privacy Notice